University of Cambridge

Markus Engelhard specializes in life sciences, pharmacology, and biotechnology, focusing on therapeutic biomolecules and pharmaceutically active agents. He supports various clients in intellectual property rights, patent portfolios, and legal proceedings. Engelhard holds degrees from the University of Cambridge, Frankfurt am Main, and Witten-Herdecke, and was a postdoctoral fellow at Cambridge.

Ancient Egyptians treated complex cranial fractures but struggled with cancer. Researchers found cut marks on a skull, suggesting experimental cancer treatments, and noted cancer's presence in antiquity.

NHS seeks 150,000 volunteers for cancer research trials, including BEST4 Heartburn Health, MyMelanoma, and PROTECT-C, aiming to improve cancer diagnosis and treatment through DigiTrials initiative.

Sun Yat-sen University, founded by Sun Yat-sen with the motto 'Study Extensively, Inquire Accurately, Reflect Carefully, Discriminate Clearly, Practice Earnestly,' has developed into a comprehensive, research-oriented university with strong academic faculties and national-level research platforms. It ranks 73rd globally and focuses on interdisciplinary research and innovation, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area. The university emphasizes cultivating top-end innovative talents and has made significant contributions to national strategies and basic research.

Korea University College of Medicine hosts seminar inviting Professors Matthew Lambon-Ralph, Dorothee Auer, and Marvin M. Chun to discuss neuroscience advancements, promoting international research collaboration.

Insilico Medicine secures $100M revolving loan from HSBC to expand its AI-driven drug discovery pipeline and upgrade Pharma.AI platform, aiming to revolutionize healthcare and meet unmet clinical needs.

Authors from various institutions collaborated on a project, with A.R.M.B. and M.F.E. as originators. Experimental work was conducted by C.L.L. and F.F., and data processing by M.F.E. and L.S. Additional contributors participated in experiments and manuscript editing.

Glaucoma drug methazolamide protects against tau protein build-up in zebrafish and mice, showing promise for treating dementia and Alzheimer’s.

Cambridge researchers found a glaucoma drug, methazolamide, may protect the brain from tau protein buildup linked to Alzheimer’s and other dementias. The drug, a carbonic anhydrase inhibitor, successfully cleared tau build-up in zebrafish and improved cognitive performance in mice with tau mutations.

A glaucoma drug, methazolamide, protects against tau protein build-up in zebrafish and mice, showing promise for treating tauopathies and Alzheimer's disease.